CNSX:LOVE Cannara Biotech (LOVE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Cannara Biotech Stock (CNSX:LOVE) 30 days 90 days 365 days Advanced Chart Get Cannara Biotech alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume69,070 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCannara Biotech Inc. is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec's low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.Read More… Receive LOVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cannara Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address LOVE Stock News HeadlinesWe Like These Underlying Return On Capital Trends At Cannara Biotech (CVE:LOVE)January 10, 2025 | finance.yahoo.comCannara Biotech Hosts Investor Webcast in DecemberDecember 13, 2024 | markets.businessinsider.comStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.January 22, 2025 | Banyan Hill Publishing (Ad)Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024December 12, 2024 | financialpost.comCannara Biotech Full Year 2024 Earnings: EPS: CA$0.071 (vs CA$0.078 in FY 2023)November 26, 2024 | finance.yahoo.comCanadian Cannabis Producer Cannara Reports 43% YoY Revenue Growth, Boosts Market Share And ProfitabilityNovember 25, 2024 | benzinga.comCannara reports record growth and profitability in Q4 2023November 25, 2024 | msn.comCannara Biotech Reports Record Growth in 2024November 25, 2024 | tipranks.comSee More Headlines LOVE Stock Analysis - Frequently Asked Questions How do I buy shares of Cannara Biotech? Shares of LOVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cannara Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cannara Biotech investors own include Aurora Cannabis (ACB), FSD Pharma (HUGE), Organigram (OGI), Aurora Cannabis (ACB), Netflix (NFLX), QUALCOMM (QCOM) and Roku (ROKU). Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCNSX:LOVE CUSIPN/A CIKN/A Webcannara.ca PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (CNSX:LOVE) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cannara Biotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Cannara Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
